Donovan Quill, President and CEO, Optime Care, article featured in Healthcare Business Today on August 20, 2021.
Intestinal amebiasis is a parasitic infection of the intestines caused by a protozoan E. histolytica that can affect anyone, although it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions. People become infected by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan.
The recent availability of Humatin™ (paromomycin sulfate) for patients with acute and chronic intestinal amebiasis and as an adjunctive therapy for management of hepatic coma will require optimized drug therapy.
As part of a Humantin care program, drug management partners serve as coordinators who work with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient.
This article discusses the need for a patient-first drug management program designed specifically for Humatin to ensure care continuity across the entire patient journey, yield rich data that clinicians can use to make more informed decisions and improve the overall patient experience.
Ultimately, when it comes to treating intestinal amebiasis, a care management solution should meet the needs of everyone involved in the patient’s journey for improved patient experience, better outcomes and cost control.
